TNFSF10 and hematologic disorder: Moreover, the concept of sTRAIL fusion may also be applicable to antibodies targeting other important antigens in hematological malignancies such as CD20 and CD38 for which TRAIL fusion constructs were already described [68,69] or further novel targets such as CD52 and CD79 [53,70].